• Profile
Close

Pexacerfont as a CRF1 antagonist for the treatment of withdrawal symptoms in men with heroin/methamphetamine dependence: A randomized, double-blind, placebo-controlled clinical trial

International Clinical Psychopharmacology Jan 31, 2018

Morabbi MJ, et al. - In this work, researchers assessed the efficacy of pexacerfont, a CRF1 antagonist, for the treatment of withdrawal symptoms in men with heroin/methamphetamine dependence. Findings suggested that pexacerfont has a potential for the treatment of withdrawal from drug dependence.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay